| |
|
|
|
|
|
SurgiFrost 10 cryosurgical system is intended for use: In the USA for minimally invasive cardiac surgical procedures, including the treatment of cardiac arrhythmias. In Europe for surgical procedures, including surgical treatment of cardiac arrhhthmias.
|
Company:
Date:
September 30, 2008
|
|
|
|
|
|
|
|
|
|
CryoAblation preserves tissue and collagen matrix integrity with virtually no risk of PV stenosis. Intact endothelium minimizes risks of endocardial thrombus associated with heat-baed energy sources.
|
Company:
Date:
September 30, 2008
|
|
|
|
|
|
|
|
|
|
SurgiFrost™ is a malleable, single-use cryosurgical probe developed to treat cardiac arrhythmias during open-heart surgery. The probe will ablate cardiac tissue while a patient is undergoing a primary cardiac surgical procedure, such as coronary artery bypass grafting (CABG) or mitral valve (MV) replacement and/or repair and as part of the Maze procedure.
|
Company:
Date:
September 30, 2008
|
|
|
|
|
|
|
|
|
|
10 cm freezing segment can be configured to desired lengths and shapes for tailoring ablaion lines; malleable probe shaft with adjustable insulation sleeve. CryoAdhesion allows absolute certainty in placement of lesion lines. Adaptable to various cardiac access incisions, including: full median sternotomy open chest, small internal incisions, thoracotomy and thoracascopic access.
|
Company:
Date:
February 10, 2009
|
|
|
|
|
|
|
|
|
|
• SurgiFrost 7 and 10 use new Argon technology to rapidly achieve temperatures as cold as -160 degree C in 30 to 60 seconds
• Short ablation times allow you to perform procedures in a timely manner
• Transmural linear lesions can be produced in an open heart, or on a closed beating heart, giving you more flexibility to meet your patients’ needs
• Completes all lesion lines efficiently
|
Company:
Date:
February 10, 2009
|
|
|
|
|